Tianshan Community Cohort Establishment and Follow-up

Condition(s) studied

Study summary

This population-based cohort study on disease prevention and health promotion was established in northwest China, leveraging data from routine annual health examinations. Initiated in January 2016, the cohort enrolled nearly all residents aged 18 years and older who were registered at community healthcare centers. The program was developed to provide a comprehensive framework for disease prevention and community health promotion, with the aim of producing population-based evidence across a broad spectrum of diseases in the general population. At baseline, data were collected on participant demographics, medical and family histories, disability status, living environment, and blood biochemical parameters. Follow-up information is primarily obtained through chronic disease management programs, annual health examinations, and electrical health records. Cause-specific mortality is ascertained from local death registration systems. Biological specimens, questionnaire data, and electrical health records are systematically archived in the Biobank and Big Data Center of the People's Hospital of Xinjiang Uygur Autonomous Region.

Eligibility

Primary outcome measure(s)

• Mortality — 20 years
  All-cause and cause-specific mortality during follow-up
• Cardiovascular diseases — 20 years
  Incident disease during follow-up
• Digestive diseases — 20 years
  Incident disease during follow-up
• Endocrine diseases — 20 years
  Incident disease during follow-up
• Infections diseases — 20 years
  Incident disease during follow-up
• Benign neoplasm or Carcinoma in situ — 20 years
  Incident disease during follow-up
• Cancers — 20 years
  Incident disease during follow-up
• Genitourinary diseases — 20 years
  Incident disease during follow-up
• Haematological or immunological diseases — 20 years
  Incident disease during follow-up
• Musculoskeletal diseases — 20 years
  Incident disease during follow-up
• Neurological diseases — 20 years
  Incident disease during follow-up
• Psychiatric diseases — 20 years
  Incident disease during follow-up
• Respiratory diseases — 20 years
  Incident disease during follow-up
• Ocular diseases — 20 years
  Incident disease during follow-up
• Dermatological diseases — 20 years
  Incident disease during follow-up
• Ear and mastoid disorders — 20 years
  Incident disease during follow-up

Trial sites (1)

Other trials for the same condition